Clinical Trials
7 trialsNCT06233864 2024-04-17
A Study of the Treatment of Disitamab Vedotin in Patients With Locally Advanced or Metastatic Pancreatic Cancer
Sun Yat-sen University
Phase 2 Unknown
NCT05578287 2023-12-07
DETECT
Sun Yat-sen University
Phase 2 Unknown
NCT06078982 2023-10-12
Posterior-line Treatment With Disitamab Vedotin Plus PD-1 in Advanced HER2-low Expressing Gastric Cancer
Shanghai East Hospital
Phase 1 Unknown
NCT05649163 2022-12-16
Real-world Study of HER2-overexpressed Advanced Solid Tumors After Progression of First-line Standard Therapy
Peking University
Unknown
NCT05627414 2022-11-25
Conversion Therapy of Disitamab Vedotin Combined With Sintilimab and S-1 in HER2 Overexpression Gastric Cancer
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Unknown
NCT05493683 2022-10-21
Disitamab Vedotin Combined With Tislelizumab in Advanced HER2 Positive Colorectal Cancer
The First Affiliated Hospital with Nanjing Medical University
Phase 2 Unknown
NCT05333809 2022-04-20
Pembrolizumab and Disitamab Vedotin in HER2-expressing Metastatic Colorectal Cancer
Shanghai Zhongshan Hospital
Phase 2 Unknown